DOI: 10.1055/s-00000069

Seminars in Liver Disease

References

Llovet JM, Decaens T, Raoul J-L , et al.
Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study.
Abstract presented at: 47th Annual Meeting of the European Association for the Study of the Liver; April 18–22, 2012; Barcelona, Spain

Download Bibliographical Data

Search in: